American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1282)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2584)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (291)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8707)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (10)

More Publications

Results (9183)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with (177)Lu-PSMA-617 versus change of ARPI in PSMAfore
    Meeting Abstract

    De Bono, J. S.; Morris, M. J.; Sartor, O.; Wei, X. X.; Fizazi, K.; Herrmann, K.; Piulats, J. M.; Mahammedi, H.; Logothetis, C.; George, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Study of ELU001, a C'Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors
    Meeting Abstract

    Ma, W. W.; Tolcher, A. W.; Perez, C. A.; Hendrickson, A. E. W.; Orr, D. W.; Murciano-Goroff, Y. R.; Anders, C. K.; Hamilton, E. P.; Swisher, E. M.; Mathews, C. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Associations of prior lung diseases on risk of lung cancer in populations with no smoking history: A systematic review and meta-analysis
    Meeting Abstract

    Swami, N.; Hong, J. H.; Kho, S.; Kang, H.; Lin, L.; Ni, S.; Dee, E. C. C.; Florez, N.; Gomez, S. L.; Cheng, I.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Azad, A.; Musto, C.; Netanel, S.; Zhang, T.; Rathkopf, D. E.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Runcie, K.; Dos Santos, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)
    Meeting Abstract

    Barlesi, F.; Felip, E.; Popat, S.; Solomon, B. J.; Wolf, J.; Li, B. T.; Wu, Y. L.; Kerr, K.; Akamatsu, H.; Camidge, D. R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL)
    Meeting Abstract

    Freedland, S. J.; Mulhall, J.; Gleave, M.; De Giorgi, U.; Rannikko, A.; Saad, F.; Ramirez-Backhaus, M.; Ivanova, J. I.; Nasr, A. F.; Ganguli, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2- breast cancer (BC)
    Meeting Abstract

    Juric, D.; Patel, M. R.; Duska, L. R.; Jhaveri, K. L.; Henick, B. S.; Matulonis, U. A.; Munster, P. N.; Birrer, M. J.; Moore, K. N.; Curigliano, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma
    Meeting Abstract

    Mora, J.; Chan, G. C.; Morgenstern, D. A.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; Rubio-San-Simón, A.; Eldridge, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202
    Meeting Abstract

    Muro, K.; Chin, K.; Maron, S. B.; Braiteh, F. S.; Mitani, S.; Hara, H.; Kuboki, Y.; Mulcahy, M. F.; Baranda, J. C.; Gardner, F. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
    Meeting Abstract

    Andre, F.; Hamilton, E. P.; Loi, S.; Anders, C. K.; Schmid, P.; Stroyakovskiy, D.; Villanueva, R.; Pedrini, J. L.; Doval, D. C.; Zurawski, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save